The HDDC3 Knockout Jurkat Polyclonal Cells product provides a CRISPR/Cas9-edited polyclonal knockout cell population targeting the HDDC3 gene in the Jurkat T-lymphocyte host line. This loss-of-function model is generated through CRISPR/Cas9-mediated gene disruption, yielding a heterogeneous pool of edited cells that collectively ablate HDDC3 expression. As a polyclonal product, it captures diverse editing outcomes without clonal selection, enabling robust functional studies while avoiding the artifacts of single-cell expansion. The population format is particularly suited for experiments demanding biological replicates that reflect the complexity of mixed genotypes, and it serves as a versatile platform for investigating HDDC3-dependent molecular processes.
Jurkat cells are an immortalized CD4+ T-cell line originally derived from a 14-year-old male with acute T-cell leukemia (T-ALL). This widely used model recapitulates key aspects of T-cell receptor signaling, antigen response, and leukemic transformation, making it a cornerstone for studying T-cell biology and hematological malignancies. Jurkat cells exhibit constitutive NF-??B activity, which is often dysregulated in T-ALL, and they respond robustly to upstream stimuli through canonical signaling cascades. The cell line??s well-characterized signaling networks and ease of genetic manipulation establish it as an optimal host for interrogating the function of HDDC3 in a pathophysiologically relevant context.
HDDC3 encodes a mitochondrial 5′-nucleotidase essential for maintaining mitochondrial deoxyribonucleotide triphosphate (dNTP) pools and a dual-function protein phosphatase that dephosphorylates the NF-??B subunit RelA (p65). By removing phosphates from RelA, HDDC3 dampens NF-??B transcriptional activity, directly opposing the I??B kinase complex (IKK??)-mediated phosphorylation of I??B?? that liberates RelA. Consequently, HDDC3 functions as a negative regulator of NF-??B signaling, modulating the expression of downstream targets such as the pro-inflammatory cytokines IL2 and TNFA. The protein interacts directly with RelA and with mitochondrial nucleoside kinases, integrating metabolic and signaling cues. Upstream regulators include NF-??B pathway activation, cellular stress responses, and mitochondrial biogenesis signals, placing HDDC3 at a nexus of bioenergetic and immune signaling control.
In Jurkat T-ALL cells, disruption of HDDC3 is anticipated to relieve the phosphatase-mediated inhibition of RelA, resulting in heightened NF-??B activity. This enhanced signaling can drive transcription of proliferative and survival genes, potentially exacerbating leukemic phenotypes. Simultaneously, loss of mitochondrial 5′-nucleotidase function may deplete dNTP pools, creating an imbalance in nucleotide metabolism that could affect mitochondrial DNA synthesis and cell cycle progression. The interplay between amplified NF-??B responses and altered metabolic homeostasis in this polyclonal knockout system provides a unique experimental paradigm to dissect the dual roles of HDDC3, particularly in the context of T-cell malignancies where both NF-??B and mitochondrial function are frequently perturbed.
This product supports a wide array of research applications, including the quantification of NF-??B pathway activation via Western blotting for phosphorylated RelA and I??B??, or NF-??B luciferase reporter assays. Functional outcomes such as T-cell activation can be monitored by flow cytometric analysis of CD69 expression, while RT-qPCR measures transcriptional changes of canonical NF-??B target genes like IL2 and TNF. Mitochondrial dNTP levels may be assessed by liquid chromatography-mass spectrometry (LC-MS), and cellular fitness evaluated through MTT or EdU incorporation assays. Co-immunoprecipitation experiments enable examination of physical interactions between HDDC3 and RelA. For additional product inquiries, please contact Ascent Research.
